Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide-1 Receptor Agonists

Details

Files

Project Status:

Completed

Project Line:

Health Technology Review

Project Sub Line:

Technology Review

Project Number:

HC0087-000

Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat type 2 diabetes. Some of these drugs are also used for weight management. Recently, there have been reports of suicide or self-harm in patients treated with these drugs. This report critically appraised published observational studies evaluating suicidality and self-harm behaviours among patients with type 2 diabetes, and patients with obesity who do not have diabetes, treated with GLP-1 receptor agonists.

Files

Exploration of the Risk of Suicidality and Self-Harm With Glucagon-Like Peptide… View PDF

Final Summary Report View PDF

Last Updated : May 16, 2024